IL-1 inhibition is already being tested as a possible treatment alternative for different cancers, such as myeloma, breast, pancreatic and colorectal cancers, and there are in vivo animal studies showing promising results for HNSCC treatment. This evidence concerns the gene IL1B and head and neck squamous cell carcinoma.